These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 12645035

  • 1. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E, Bergman J, Eskola O, Solin O, Vahlberg T, Sonninen P, Rinne JO.
    Synapse; 2003 Jun 01; 48(3):109-15. PubMed ID: 12645035
    [Abstract] [Full Text] [Related]

  • 2. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
    Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, Rinne JO.
    J Cereb Blood Flow Metab; 2000 Nov 01; 20(11):1604-9. PubMed ID: 11083235
    [Abstract] [Full Text] [Related]

  • 3. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
    Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO.
    Ann Neurol; 2000 Jun 01; 47(6):804-8. PubMed ID: 10852547
    [Abstract] [Full Text] [Related]

  • 4. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ, Nurmi E, Ruottinen HM, Bergman J, Eskola O, Solin O.
    Synapse; 2001 Jun 01; 40(3):193-200. PubMed ID: 11304757
    [Abstract] [Full Text] [Related]

  • 5. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR, Votaw JR, Bremner JD, Byas-Smith MG, Faber TL, Voll RJ, Hoffman JM, Grafton ST, Kilts CD, Goodman MM.
    J Nucl Med; 2003 Jun 01; 44(6):855-61. PubMed ID: 12791810
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O.
    J Neurol Neurosurg Psychiatry; 1999 Dec 01; 67(6):737-41. PubMed ID: 10567489
    [Abstract] [Full Text] [Related]

  • 7. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
    Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, Rinne JO.
    Mov Disord; 2001 Jul 01; 16(4):608-15. PubMed ID: 11481683
    [Abstract] [Full Text] [Related]

  • 8. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.
    Brain; 2001 Apr 01; 124(Pt 4):784-92. PubMed ID: 11287377
    [Abstract] [Full Text] [Related]

  • 9. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease.
    Rinne JO, Bergman J, Ruottinen H, Haaparanta M, Eronen E, Oikonen V, Sonninen P, Solin O.
    Synapse; 1999 Feb 01; 31(2):119-24. PubMed ID: 10024008
    [Abstract] [Full Text] [Related]

  • 10. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.
    J Nucl Med; 1998 Jul 01; 39(7):1143-8. PubMed ID: 9669384
    [Abstract] [Full Text] [Related]

  • 11. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
    Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D.
    Neuroimage; 2004 Apr 01; 21(4):1497-507. PubMed ID: 15050574
    [Abstract] [Full Text] [Related]

  • 12. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS.
    Ann Neurol; 1990 Oct 01; 28(4):547-55. PubMed ID: 2132742
    [Abstract] [Full Text] [Related]

  • 13. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
    Brück A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO.
    Mov Disord; 2006 Jul 01; 21(7):958-63. PubMed ID: 16550545
    [Abstract] [Full Text] [Related]

  • 14. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A, Valldeoriola F, Lomeña F, Molinuevo JL, Serradell M, Salamero M, Cot A, Ros D, Pavía J, Santamaria J, Tolosa E.
    Lancet Neurol; 2011 Sep 01; 10(9):797-805. PubMed ID: 21802993
    [Abstract] [Full Text] [Related]

  • 15. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T.
    J Neurol Sci; 2001 Jun 15; 187(1-2):55-9. PubMed ID: 11440745
    [Abstract] [Full Text] [Related]

  • 16. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.
    Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J.
    Nucl Med Commun; 2001 Jun 15; 22(6):721-5. PubMed ID: 11403185
    [Abstract] [Full Text] [Related]

  • 17. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
    Gallagher CL, Oakes TR, Johnson SC, Chung MK, Holden JE, Bendlin BB, McLaren DG, Xu G, Nickles RJ, Pyzalski R, DeJesus O, Brown WD.
    Mov Disord; 2011 Mar 15; 26(4):614-20. PubMed ID: 21449008
    [Abstract] [Full Text] [Related]

  • 18. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, Audrain H, Bender D, Østergaard K, Brooks DJ, Borghammer P.
    Brain; 2016 Jul 15; 139(Pt 7):2039-49. PubMed ID: 27190023
    [Abstract] [Full Text] [Related]

  • 19. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
    Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona CL.
    Neurology; 2004 May 11; 62(9):1568-72. PubMed ID: 15136683
    [Abstract] [Full Text] [Related]

  • 20. Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease.
    Li X, Zhang Q, Qin Y, Li Y, Mutaerbieke N, Zhao X, Yibulayin A.
    Medicine (Baltimore); 2020 Apr 11; 99(14):e19662. PubMed ID: 32243399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.